Weeks (W) after treatment | ||||
---|---|---|---|---|
W0 | W2 | W12 | W24 | |
DAS28 | 6.17 ± 0.86 | 4.365 ± 1.12*** | 3.62 ± 1.32*** | 3.43 ± 1.26*** |
US7 | 8.7 ± 8.61 | 3.1 ± 3.09** | 2.35 ± 2.85** | 2.1 ± 2.51** |
MMP-3 | 214.8 ± 160.4 | 94.11 ± 74.96*** | 98.86 ± 114.7*** | 122.7 ± 167.7* |
CRP | 12.40 ± 15.01 | 6.05 ± 7.338 | 5.45 ± 8.27** | 6.5 ± 15.22 |
Anti-CCP | 363.0 ± 385.6 | 386.7 ± 454.2 | 339 ± 374.2 | 300.3 ± 323.7 |
HAQ | 22.2 ± 14.7 | 13.85 ± 10.64*** | 12.5 ± 9.95** | 12.9 ± 10.7*** |
ESR | 60.35 ± 22.78 | 38.95 ± 16.96*** | 29.75 ± 14.59*** | 37.0 ± 21.8*** |
Synovitis | 3.70 ± 3.511 | 2.35 ± 2.98* | 2.25 ± 2.845* | 1.3 ± 2.658** |
Synovial blood flow | 1.85 ± 2.368 | 0.85 ± 1.63* | 0.65 ± 1.424* | 0.4 ± 0.821** |
Tenosynovitis | 0.25 ± 0.71 | 0.05 ± 0.22 | 0.05 ± 0.23 | 0 |
Tenosynovial blood flow | 0.25 ± 0.71 | 0 | 0 | 0 |
Bone erosion | 0.65 ± 1.13 | 0.5 ± 1.0 | 0.45 ± 0.99 | 0.3 ± 0.57 |